GT Biopharma (GTBP) Appoints Hilary Kramer to its Board
Get Alerts GTBP Hot Sheet
Join SI Premium – FREE
GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary TriKE® natural killer (NK) cell engager platform, today announced the appointment of Hilary Kramer to its Board of Directors. Mrs. Kramer will be replacing current board member Bruce Wendel, who is resigning his position.
“We are delighted to welcome Hilary to the Board of Directors at this exciting time, and we look forward to leveraging her expertise as we continue to make great clinical progress with our NK engagers,” said Michael Breen, Executive Chairman and Chief Executive Officer of GT Biopharma. “Hilary is an experienced executive with a strong strategic and operational background. She is an important addition to the board as the Company evolves in its next phase of maturation as a clinical stage biotech company.”
Mrs. Kramer is the Founder and Chief Investment Officer of GreenTech Research, the very first U.S.-based sustainable fund and publisher of growth equity research and global market forecasting. She actively oversees portfolio strategy, positioning, hedging, and fund allocations. Mrs. Kramer has served on the boards of several public companies, including RSL Communications Ltd., Deltathree Inc., El Sitio Inc., and INX Digital, and was a member of the Advisory Boards for DirecTV International and Ibero-American Media Partners.
Previously, she was Senior Managing Director and Chief Investment Officer for a $12 billion family office portfolio, where she developed the investment strategy, managed diversified equity and fixed-income portfolios, and directed private equity investments. She has been a consultant at Freddie Mac, Montgomery Asset Management and to families offices. Her earlier career includes investment banking at Lehman Brothers and Morgan Stanley, as well as brand management at General Mills. Mrs. Kramer holds a B.A. with honors in Political Science and Latin American Studies from Wellesley College and an MBA from the Wharton School of the University of Pennsylvania.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- McEwen Copper seeks $1.6b in equity financing for Los Azules - Bloomberg
- EyePoint Pharmaceuticals (EYPT) call put ratio 1.4 calls to 1 put as share price up 8.9%
- SEC proposes rules to create regime for some crypto contracts
Create E-mail Alert Related Categories
Board Changes, Corporate NewsRelated Entities
Morgan Stanley, Lehman Brothers, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share